Biomarkers Products & Reviews

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S1) is a recombinant antigen which contains the Spike protein amino acids 1-674. Spike S1 protein is manufactured in HEK293 mammalian cells, ensuring the most authentic post-translational modifications.

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike S2 protein, amino acids 685-1211. Spike S2 is manufactured in mammalian HEK293 cells to ensure the most authentic post-translational modifications.

The Native Antigen Company offers a selection of complementary easy-to-use antibody conjugation formats, with a wide range of labels suitable for use in most applications. On request we can also undertake custom conjugation of proteins and antibodies.

With decades of experience in the field of native antigen and recombinant protein production, and assay development, The Native Antigen Company is able to undertake a wide range of custom projects on your behalf.  

SARS-CoV-2 Nucleoprotein is a recombinant antigen manufactured in E. coli cells to high purity for use in vaccine research and immunoassay development. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

SARS-CoV-2 Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike protein amino acids 685-1211 of subunit 2. Spike S2 protein is manufactured to high yield and purity using the Native Antigens baculovirus-insect cell platform. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

SARS-CoV-2 Spike-E-M Mosaic protein is a recombinant antigen manufactured in E. coli with greater than 95% purity, and containing the Spike (S), Envelope (E) and Membrane (M) immunodominant regions. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

Human Coronavirus 229E Nucleoprotein is a recombinant protein containing 359 amino acids derived from the nucleocapsid sequence, with a C-terminal 6xHis tag. It is manufactured in E. coli with greater than 95% purity.

Human Coronavirus NL63 Nucleoprotein is a recombinant protein containing the nucleocapsid C-terminal region (130 amino acids), cloned and expressed in E. coli, and purified by affinity chromatography (nickel column) with greater than 95% purity.

The first and only blood test authorized in the U.S. for use as a prognostic marker in patients with advanced fibrosis due to MASH

KREX™ i-Ome™ Discovery Services enable highly multiplexed autoantibody profiling for rapid, reproducible discovery across diverse diseases. The platform measures antibody binding to 1,800+ full-length, correctly folded human proteins – preserving conformational epitopes for highly specific and biologically relevant autoantibody detection. It provides valuable insight into immune responses in health, disease and treatment.

Biomarker assays are laboratory methods that detect or analyse genes, proteins, or other molecules in biological samples and are fundamental tests in biotherapeutic drug monitoring, research, and development. Prolytix offers comprehensive biomarker assay development, validation, and testing services.

Recombinant SARS-CoV-2, S1 Subunit Protein (RBD) with C-terminal His tag, derived from the transfected human HEK293 cells.

Recombinant SARS-CoV-2 Spike Protein, S1 Subunit derived from E.coli

Single molecule array (Simoa) testing is a protein detection technique that is orders of magnitude more sensitive than standard sandwich based immunoassay techniques. Traditional ELISA measurements are limited to pg/ml levels of detection. The RayBio Ultrasensitive Simoa Testing Services can achieve sensitivity as low as femtogram (fg/ml) levels, allowing the quantification of biomarkers at concentrations previously difficult…